Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fountain Therapeutics Inc. announced that it has received $15.864168 million in funding from Eli Lilly and Company, Alexandria Venture Investments, LLC, R42 Group, Khosla Ventures, LLC, Nan Fung Life Sciences, and otherinvestors

11/18/2021 EST

On November 18, 2021, Fountain Therapeutics, Inc closed the transaction. The transaction included participation from new investors Eli Lilly and Company, Alexandria Venture Investments, LLC, R42 Group, returning investors Khosla Ventures, LLC and Nan Fung Life Sciences. This round of funding brings its total Series A funding to $26 million. The company has raised funding pursuant to Regulation D from eight investors.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
01/21Innovent and Eli Lilly and Company Announces Final Clinical Results and Biomarker Analy..
CI
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
01/21DZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
MT
01/20Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial..
PR
01/19Iterative Scopes, Inc announced that it has received $150 million in funding from Insig..
CI
01/18Evotec, Eli Lilly to Collaborate on Treatments for Metabolic Diseases
MT
01/18Evotec, Eli Lilly to Address Kidney Diseases, Diabetes in Three-Year Drug Discovery Col..
MT
01/18Eli Lilly, Evotec Team Up to Discover Drugs For Metabolic Diseases
MT
01/18Evotec SE Enters into a Drug Discovery Collaboration with Eli Lilly and Company
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 946 M - -
Net income 2021 6 022 M - -
Net Debt 2021 11 909 M - -
P/E ratio 2021 37,8x
Yield 2021 1,37%
Capitalization 220 B 220 B -
EV / Sales 2021 8,31x
EV / Sales 2022 8,19x
Nbr of Employees 35 000
Free-Float -
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 243,06 $
Average target price 284,18 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-11.98%220 356
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
NOVO NORDISK A/S-14.11%219 146